## Multi Drug Resistance Gene Single Nucleotide Polymorphisms in Inflammatory Bowel Disease

K. Katsanos<sup>1,2</sup>, Séverine Vermeire<sup>1</sup>, Karolien Claes<sup>1</sup>, Nele Van Schuerbeek<sup>1</sup>, Gert Van Assche<sup>1</sup>, P. Rutgeerts<sup>1</sup>, E.V. Tsianos<sup>2</sup>

The multidrug resistance gene (MDR) is a typical stress-response gene and is highly polymorphic. Most of the detected polymorphisms are intronic or silent.<sup>1</sup> In humans, 2 members of the MDR gene family (MDR1 and MDR3) exist, whereas 3 genes are present in rodents-mdr1a, mdr1b and mdr2.<sup>2</sup>

The MDR1 gene product, P-glycoprotein (PGP), was initially observed as a transport protein which was overexpressed in tumors developing resistance to chemotherapeutic agents, resulting from PGP-mediated efflux of drug from tumor cells. The physiological role of PGP although not fully understood, involves hormone and metabolite secretion, bacterial product detoxification, and transport of several drugs to the extracellular space, thus inhibiting their toxic or therapeutic effects.<sup>3</sup>

The human MDR gene is composed of 28 exons. To date 29 SNPs have been reported in the MDR1 gene. Among polymorphisms within MDR1, there has been some controversy regarding the functional significance of a missense polymorphism within exon 21 (G2677T/C-Ala893Ser/Thr) and of a wobble polymorphism within exon 26 (C3435T-II1145Ile). Various reports have suggested that one or the other are associated with altered transporter or gene expression activity.<sup>1</sup>

<sup>1</sup>Division of Gastroenterology, University of Leuven Hospitals, Leuven-3000, Belgium, 21st Department of Internal Medicine (Hepato-Gastroenterology Unit), University Hospital of Ioannina, Greece

Author for correspondence:


Dr Epameinondas V. Tsianos, Professor of Internal Medicine, 1st Division of Internal Medicine, Medical School, University of Ioannina, Leoforos Panepistimiou, 451 10 Ioannina, Greece, Tel: 0030-26510-097501, Fax: 00-30-26510-097016, e-mail: etsianos@cc.uoi.gr It is significant that, although developmentally normal, *mdr1*-deficient mice spontaneously develop colitis.<sup>4</sup> This suggests that functional polymorphisms within MDR1, which result in a loss of or decrease in PGP activity, might increase susceptibility to IBD. Epidemiologic studies have observed a lower incidence of IBD in Africans as compared to Caucasians, consistent with the ethnic differences in the allelic frequency of polymorphism in exon 26.<sup>1</sup> In a case-control study by Schwab et al.<sup>5</sup> the C3435T variant was found to be significantly associated with UC but not with CD. However, these results were not confirmed in the Greek UC population.<sup>6</sup>

Brant et al.<sup>2</sup> observed a significant association of CD with the Ala893 variant, which has been associated with decreased activity relative to the 893Ser variant as shown by Kim et al.<sup>7</sup> Furthermore, no evidence for UC or CD association for the 3435T was observed. Ho et al<sup>8</sup> showed that the MDR1 3435TT genotype and T-allelic frequencies were significantly higher in patients with UC-especially in those with extensive disease- compared with controls. No associated with UC or CD.

**Key words:** multidrug resistant gene, P-glycoprotein, polymorphism, inflammatory bowel disease, ulcerative colitis, Crohn's disease

## Abbreviations

CD=Crohn's disease IBD=Inflammatory bowel disease MDR1 = multidrug resistance gene 1 (human) mdr1 = multidrug resistance gene 1 (murine) PGP=P-glycoprotein (the MDR1 gene product) SNP(s) = single nucleotide polymorphism(s) UC=ulcerative colitis



**Fig.** Multidrug resistance (MDR1) gene single nucleotide polymorphisms of possible importance in inflammatory bowel disease: G2677A, G2677T and C3435T. (Agarose gel electrophoresis of digested PCR product, W/W=Homozygous wild type, M/M=Homozygous mutated, W/M=heterozygous).

| Author                                      | MDR1 SNP<br>of importance                                   | No controls   | No UC      | No CD | Significantly increased in        | IBD phenotype   |
|---|---|---|------------|-------|-----------------------------------|---|
| Katsanos et al<br>(submitted)               | C3435T  | 383   | 121        | 716   | CD (T allele)                     | -Stronger association<br>with fistulizing CD<br>-No association with UC   |
| Ho et al <sup>8</sup>                       | C3435 T   | 370   | 335        | 268   | UC<br>(T allele & TT<br>genotype) | -Strongest association in<br>extensive UC<br>-No association with CD      |
| McGovern et al <sup>14</sup>                | C3435T  | 247   | 272        | -     | UC<br>(T allele)                  | Included in a serology<br>panel predicting<br>colectomy in UC             |
| Schwab et al <sup>5</sup>                   | C3435T  | 275 (Age-sex<br>matched)<br>998 (non sex-<br>matched) | 149        | 126   | UC<br>(TT genotype)               | No association with CD  |
| Brant et al <sup>2</sup><br>cant            | G2677T  | 650   | 119        | 409   | CD                                | Similar but non-signifi-  |
|   |   |   |            |       | (G allele)                        | trends in UC  |
| Farrell et al <sup>11</sup>                 | MDR in<br>peripheral blood<br>lympocytes<br>(low cytometry) | 50  | 153<br>IBD |       | CD                                | CD patients requiring<br>bowel resection after<br>medical therapy failure |
| Croucher et al <sup>10</sup>                |   |   |            |       |                                   |   |
| (German cohort)                             |   |   |            |       |                                   |   |
|   | C3435T  | 531   | 134        | 262   | NONE<br>(UC or CD)                |   |
| Croucher et al <sup>10</sup><br>(UK cohort) | C3435T  | 164   | 87         | 164   | NONE<br>(UC or CD)                |   |
| Glas et al <sup>12</sup><br>geno-           | C3435T  | 265 (2 groups)  | 123        | 135   | NONE                              | Trend for T allele/TT   |
|   |   |   |            |       | (UC or CD)                        | type association with UC  |
| Gazouli et al <sup>6</sup>                  | C3435T  | 100   | 85         | 120   | NONE                              | Absence of CC genotype  |
| Potocnik et al <sup>13</sup>                | C3435T<br>G2677T<br>C1236T                                  | 355   | 144        | 163   | CD and UC                         | Refractory and fistulizing CD and refractory UC                           |

**Table.** Overview of the reported prevalence of MDR1 single nucleotide polymorphisms G2677T/A and C3435T and their relation to disease phenotype in patients with inflammatory bowel disease

A unifying model for genes that increase susceptibility to IBD is that they fundamentally affect host-environment interactions. Just as NOD2/CARD15 risk alleles result in decreased responsiveness to bacterial cell wall products, the Ala893 variant in MDR1 has been associated with relatively decreased transporter function.

A remarkably large number of MDR1 genotype-phenotype studies have been carried out by many laboratories<sup>9-14</sup> and as noted previously, a number of such studies have yielded conflicting results which are summarized in Table. PGP is widely expressed in many normal tissues including enterocytes, hepatocytes, brain choroids plexus, placenta, ovaries and testes. Gender differences have also been noted in the MDR1hepatic expression with women displaying only one third to one half of the hepatic PGP level of men.<sup>15</sup>

To minimize the chance of a spurious association between MDR1 genotypes and in vivo phenotypes, careful attention must be paid to haplotypes, gender, environmental factors and sample size. Indeed, such studies should try to ensure that demographic data of subjects selected for the various MDR1 SNPs do not differ.

## ACKNOWLEDGMENTS

-Dr Konstantinos H. Katsanos is an international grant recipient of the Hellenic Society of Gastroenterology.

- Dr Swerine Vermeire and Dr Gert Van Assche are funded by the Flemish Foundation for Scientific Research (FWO).

## REFERENCES

- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevancy. Clin Pharmacol Ther 2004;75:13-33
- Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003;73:1282-1292
- Richaud-Patin Y, Vega-Boada F, Vidaller A, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother 2004;58:320-324
- Panwala CM, Lones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneous develop colitis. J Immunol 1998;161:5733-5744
- Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33
- Gazouli M, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonomopoulos I. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology 2004;126:367-369

- Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199
- Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005;128:288-296
- Cascorbi I, Gerloff T, Lohne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174
- Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastoenterology 2003;125:1919-1920
- Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-288
- Glas J, Torok HP, Schiemann U, Folwaczny C. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology 2004;126:367
- Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance (MDR1) gene are associated with refractory Crohn's disease and ulcerative colitis. Genes Immun 2004;5:530-539
- Mc Govern D, Ahmad T, van Heel D, Jewell DP. A genetic panel strongly predicts the need for colectomy in ulcerative colitis. Gastroentrology 2004;126:Abstr.525
- Yi S-Y, Hong K-S, Lim H-S, Chung J-Y, Oh D-S, Kim J-R, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004; 76:418-427